| Trial ID: | L3614 |
| Source ID: | NCT02877355
|
| Associated Drug: |
Semaglutide
|
| Title: |
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: semaglutide
|
| Outcome Measures: |
Primary: Area under the semaglutide plasma concentration-time curve, From 0 to 24 hours after the 10th dosing | Secondary: Maximum observed semaglutide plasma concentration, From 0 to 24 hours after the 10th dosing|Area under the SNAC plasma concentration-time curve, During a dosing interval (0 to 24 hours) at steady state|Maximum observed SNAC plasma concentration, During a dosing interval (0 to 24 hours) at steady state
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
55
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-08-22
|
| Completion Date: |
2017-11-24
|
| Results First Posted: |
|
| Last Update Posted: |
2019-04-29
|
| Locations: |
Novo Nordisk Investigational Site, Mainz, 55116, Germany|Novo Nordisk Investigational Site, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02877355
|
